https://ichgcp.net/es/news/navigen-inc-started-a-new-clinical-trial-of-a-phase-ia-clinical-study-of-hiv-entry-inhibitor-cpt31-single-ascending-dose-study-of-safety-tolerability-immunogenicity-and-pharmacokinetics-in-healthy-adults